A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA)

PHASE1CompletedINTERVENTIONAL
Enrollment

11

Participants

Timeline

Start Date

October 26, 2012

Primary Completion Date

July 28, 2016

Study Completion Date

July 13, 2017

Conditions
Juvenile Idiopathic Arthritis
Interventions
DRUG

Tocilizumab

Tocilizumab will be administered as indicated in the arm description.

Trial Locations (20)

1094

Semmelweis University; 2nd Department of Paediatrics, Budapest

1270

Hospital Gral de Niños Pedro Elizalde, Buenos Aires

3000

UZ Leuven Gasthuisberg, Leuven

9000

UZ Gent, Ghent

15224

Children's Hospital Of Pittsburgh, Pittsburgh

28177

Klinik Bremen-Mitte; Prof. Hess-Kinderklinik, Bremen

40202

University of Louisville Research Foundation, Inc; Kosair Charities Pediatric Clinical Research Unit, Louisville

46026

Hospital Universitario la Fe: Servicio de Reumatologia Pediatrica, Valencia

60649

The University of Chicago;Department of Pediatrics, Chicago

89109

Children's Speciality Center of Nevada, Las Vegas

20010-2970

Children's National Medical Center; Pediatric Rheumatology, Washington D.C.

02111

The Floating Hospital for Children at Tufts Medical Center, Boston

02115

Children's Hospital Boston Pediatric Medicine, Boston

07601

Hackensack University Medical Center; Pediatric Rheumatology, Hackensack

45229-3039

Cincinnati Children'S Hospital Medical Center; Division of Rheumatology, Cincinnati

T3B 6A8

Alberta Children'S Hospital, Calgary

M5G 1X8

Hospital For Sick Children, Toronto

H4A 3J1

McGill University; Montreal Children's Hospital; Inflammatory, Autoimmune & Bone, Montreal

91-738

Uniwersytecki Szpital Kliniczny Nr 4 im. M. Konopnickiej; Oddz. Kardiolog. i Reumatolog. dla Dzieci, Lodz

20-093

Uniwersytecki Szpital Dzieciecy w Lublinie; Oddzial Pediatrii, Chorob Pluc i Reumatologii, Lublin

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT01455701 - A Study to Evaluate Pharmacokinetics and Safety of Tocilizumab (RoActemra/Actemra) in Participants Less Than 2 Years Old With Active Systemic Juvenile Idiopathic Arthritis (sJIA) | Biotech Hunter | Biotech Hunter